Close Menu

Oppenheimer

The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.

The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.

Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares.

NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer.

NEW YORK (GenomeWeb News) – Anticipating the expected launch of the Life Technologies' Ion Proton benchtop sequencer, Oppenheimer analyst David Ferreiro today estimated 140 placements of the system in 2012 translating to $35.3 million in revenues.

NEW YORK (GenomeWeb News) – Investment bank Oppenheimer has initiated coverage of Genomic Health, Thermo Fisher Scientific, and Fluidigm.

According to Oppenheimer, Sequenom will hire 20 sales representatives for the test by the end of August and has contacted 28 payors for reimbursement of the test, of which 25 have responded with "encouraging" feedback.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.